P4 Diagnostix Laboratory Network announced the acquisition of Metamark Laboratories, Inc., formerly a division of Metamark Genetics, Inc.

The acquisition of Metamark Laboratories expands the geographic reach, insurance base, and urology testing portfolio of P4 Diagnostix Laboratory Network (P4).

"We are eager to combine efforts with Metamark Laboratories, which will allow us to expand our commitment to our clients and patients providing greater depth in our services to improve outcomes," said Sathish Reddy, CEO, adding "all P4 laboratory divisions will work closely and act as distribution partners for MetaMark Genetics' novel biomarker assays, including ProMark, the first proteomic classifier of biopsied prostate tissue that assesses whether an early-stage prostate tumor is aggressive or indolent, aiding important treatment decisions."

P4 welcomes thousands of new patients to our in-network offering with the expansion of insurance contracts through Metamark Laboratories, including, but not limited to, Blue Cross and Blue Shield of Texas, Anthem Blue Cross Blue Shield of Georgia and Highmark Blue Cross Blue Shield.

P4 is comprised of four laboratory companies, including Theranostix, Inc. (Beltsville, MD and Brick, NJ), Long Island Pathology, Inc. (East Setauket, NY), Platinum Pathology, LLC (Glen Allen, VA) and Metamark Laboratories, Inc. (Augusta, GA). P4 represents a progressive pathway in healthcare focused on predictive, preventative, personalized and participatory medical practice, beyond diagnosing and treating disease.

Metamark Genetics, Inc. is a privately-held biotechnology company founded to develop novel, function-based prognostic and diagnostic tests aimed at improving urological cancer care. Through the acquisition of HealthTronics Laboratory Solutions in 2013, Metamark has become a leading provider of specialty urological pathology testing services with the first fully integrated clinical model for the prostate cancer care pathway.